00-0000000 0001808158 false 0001808158 2024-08-01 2024-08-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 1, 2024

 

 

Repare Therapeutics Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Québec   001-39335   Not applicable

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

7171 Frederick-Banting, Building 2

Suite 270

St-Laurent, Québec, Canada

   H4S 1Z9
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (857) 412-7018

Not Applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol

  

Name of each exchange

on which registered

Common shares, no par value   RPTX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On August 1, 2024, Briggs Morrison, M.D. notified the board of directors (the “Board”) of Repare Therapeutics Inc. (the “Company”) of his decision to resign as a Class III director and as chair of the Science and Technology Committee of the Board, effective as of August 6, 2024. In connection with Dr. Morrison’s resignation, Steven H. Stein, M.D. replaced Dr. Morrison as chair of the Science and Technology Committee, effective as of August 6, 2024. Dr. Morrison’s decision was not the result of any disagreement between Dr. Morrison and the Company, its management, the Board or any committees thereof on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

REPARE THERAPEUTICS INC.
By:  

/s/ Lloyd M. Segal

 

Lloyd M. Segal

President and Chief Executive Officer

Dated: August 7, 2024

v3.24.2.u1
Document and Entity Information
Aug. 01, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 01, 2024
Entity Registrant Name Repare Therapeutics Inc.
Entity Incorporation State Country Code A8
Entity File Number 001-39335
Entity Tax Identification Number 00-0000000
Entity Address Address Line 1 7171 Frederick-Banting, Building 2
Entity Address Address Line 2 Suite 270
Entity Address City Or Town St-Laurent
Entity Address State Or Province QC
Entity Address Country CA
Entity Address Postal Zip Code H4S 1Z9
City Area Code 857
Local Phone Number 412-7018
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common shares, no par value
Trading Symbol RPTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001808158
Amendment Flag false
Repare Therapeutics (NASDAQ:RPTX)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Repare Therapeutics.
Repare Therapeutics (NASDAQ:RPTX)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Repare Therapeutics.